Skip to main content

Endotronix Joins American Heart Association’s Center for Health Technology & Innovation to Broaden the Use of Guideline-Based Care for Heart Failure Patients

Announces targeted commercial launch of the Cordella Heart Failure System in the U.S.

LISLE, IL (June 28, 2018) – Endotronix Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced they have joined the American Heart Association’s Center for
Health Technology & Innovation’s (CHTI) Innovators Network. The collaboration allows Endotronix to integrate the Association’s digital resources into the Cordella™ Heart Failure System to support guideline-based care. The system is currently in commercial use in the U.S.
In the US, nearly 6 million people suffer from heart failure and it is the leading cause of hospitalization in people over the age of 651. With high mortality rates, frequent hospital readmissions and annual treatment costs over $31B in the U.S., there is a need for better proactive management and coordination of care for patients with
chronic heart failure1,2.

The collaboration between Endotronix and the Association aims to shift the heart failure care paradigm and improve at-home care management by coupling Endotronix’s Cordella System with the Association’s patient
education materials and content. Endotronix joins the Association’s Center for Health Technology & Innovation Innovators Network with a comprehensive heart failure management system, designed to streamline clinical workflow. The Cordella System allows physicians to effectively scale HF management with the Association’s comprehensive CarePlans and
education materials to improve patient outcomes. The easy-to-use system extends clinical care into the home by collecting and securely transmitting daily patient clinical data and insights to the clinician, which enable
guideline-directed medical therapy. For suitable patients, the system seamlessly integrates pulmonary artery (PA) pressure data with a proprietary wireless, implantable sensor that is currently in late-stage clinical development. Clinical studies have demonstrated that PA pressure-guided management can reduce HF-related hospitalizations by 37% and provide a mortality benefit3,4. “This collaboration with the American Heart Association is essential as we strive to extend high-quality care into the home to improve the standard of care for chronic heart failure patients,” said Harry Rowland, Chief Executive Officer and co-Founder of Endotronix. “As we begin commercialization, it is exciting to see the impact this integration is having on strengthening the communication between heart failure patients and their clinicians, enhancing coordinated care that improves outcomes and ultimately allowing patients to enjoy life
again.” The Cordella System is currently in commercial use in the U.S. The targeted launch is expected to accelerate in anticipation of the U.S. Pivotal Study for the Cordella Pulmonary Artery Pressure Sensor, which is planned for the near future. Endotronix’s goal to advance the treatment of heart failure took a leap forward this January when they announced their successful First-in-Human (FIH) implantation of the Cordella PA Pressure Sensor and initiation of the SIRONA FIH clinical trial.

About Endotronix:
Endotronix, Inc., a digital health, medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from chronic heart failure. The
company’s comprehensive solution includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early
detection of worsening heart failure.

Learn more at
1 Mozzafarian D, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and
stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016
2 Heidenreich PA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart
Association. Circulation. 2011;123(8):933–44.
3 Abraham WT et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized control study. Lancet. 2011 Feb
4 Abraham WT et al. Pulmonary artery pressure management in heart failure patients with reduced ejection fraction significantly reduces heart failure
hospitalizations and mortality above and beyond background guideline-directed medical therapy. Abstract 902-04, ACC2015, San Diego.
Carla Benigni
SPRIG Consulting LLC
(847) 951-7430

More News

  • Why Do the Principals of Cardeation Capital Think Joining Forces Makes Sense for Innovation?

    Click the link below to listen: Medtech Talk Podcast hosted by Tom…

  • The American Heart Association’s Innovative Solution Personalizes Cardiovascular Condition Management With Tailored Engagement to Improve Population Wellness and Reduce Readmissions

    DALLAS, April 9, 2018 /PRNewswire-USNewswire/ -- Patients battling cardiovascular diseases, and even people hoping…

  • Data Science Drives Education and Insights to People with Diabetes and High Blood Pressure

    Livongo Joins American Heart Association’s Center for Health Technology and Innovation to…

  • GoMo Health Teams Up with the American Heart Association to Beat Cardiovascular Disease

    GoMo Health is excited to announce that we are joining the American…

Sign up for our mailing list